Cryoport surges 13% as Q3 revenue tops estimates

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Cryoport (CYRX.US) surged nearly 13% during regular trading to $18.10.

The company reported fiscal 2026 third-quarter revenue of $50.2 million, up 14% from a year earlier and topping the analyst consensus of $48.8 million. Adjusted EBITDA turned positive at $1.1 million, beating estimates of $551,000. Cryoport raised its full-year 2026 revenue guidance to $197 million to $199 million, though third-quarter net loss widened 56% year-over-year to $10.85 million.

Separately, Cryoport's Paris center received ISO certification, and management highlighted strategic expansion in bioservices capacity.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.